<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; practical</title>
	<atom:link href="http://www.tapanray.in/tag/practical/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Prescribing medicines by generic names…a good intent… but is it a practical proposition in India?</title>
		<link>http://www.tapanray.in/prescribing-medicines-by-generic-namesa-good-intent-but-is-it-a-practical-proposition-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=prescribing-medicines-by-generic-namesa-good-intent-but-is-it-a-practical-proposition-in-india</link>
		<comments>http://www.tapanray.in/prescribing-medicines-by-generic-namesa-good-intent-but-is-it-a-practical-proposition-in-india/#comments</comments>
		<pubDate>Mon, 06 Sep 2010 00:30:32 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[But]]></category>
		<category><![CDATA[by]]></category>
		<category><![CDATA[chemists]]></category>
		<category><![CDATA[FDC]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[good]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[intent]]></category>
		<category><![CDATA[is]]></category>
		<category><![CDATA[it]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[name]]></category>
		<category><![CDATA[names]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[practical]]></category>
		<category><![CDATA[Prescribing]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[proposition]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=378</guid>
		<description><![CDATA[Parliamentary Standing Committee for Health and Family Welfare in their recommendation to the ‘Rajya Sabha’ of the Indian Parliament on August 4, 2010, recommended prescription of medicines by their generic names. This recommendation appears to be based on the premises &#8230; <a href="http://www.tapanray.in/prescribing-medicines-by-generic-namesa-good-intent-but-is-it-a-practical-proposition-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/prescribing-medicines-by-generic-namesa-good-intent-but-is-it-a-practical-proposition-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>India and China&#8230;Practical relevance of &#8216;Priority Watch List (PWL)&#8217; status in ‘Special 301 Reports’ of America&#8230;and the REAL ‘Game Changers’</title>
		<link>http://www.tapanray.in/india-and-china-practical-relevance-of-priority-watch-list-pwl-status-in-special-301-reports-of-america-and-the-real-game-changers/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=india-and-china-practical-relevance-of-priority-watch-list-pwl-status-in-special-301-reports-of-america-and-the-real-game-changers</link>
		<comments>http://www.tapanray.in/india-and-china-practical-relevance-of-priority-watch-list-pwl-status-in-special-301-reports-of-america-and-the-real-game-changers/#comments</comments>
		<pubDate>Mon, 10 May 2010 00:30:49 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[301]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[Changers]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Game]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infringement]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[List]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[practical]]></category>
		<category><![CDATA[Priority]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[PWL]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[REAL]]></category>
		<category><![CDATA[Relevance]]></category>
		<category><![CDATA[Reports]]></category>
		<category><![CDATA[Special]]></category>
		<category><![CDATA[status]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Watch]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=430</guid>
		<description><![CDATA[Many stakeholders around the world believe that Intellectual Property Rights (IPR) environment in China is far better than what we have in India. Interestingly “2010 Special 301 Report” of the United States of America dated April 30, 2010, paints a &#8230; <a href="http://www.tapanray.in/india-and-china-practical-relevance-of-priority-watch-list-pwl-status-in-special-301-reports-of-america-and-the-real-game-changers/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/india-and-china-practical-relevance-of-priority-watch-list-pwl-status-in-special-301-reports-of-america-and-the-real-game-changers/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
